The Need for Breathing Retraining: the Elephant in the Cardiac Rehabilitation Room
1 other identifier
interventional
40
1 country
1
Brief Summary
As an extension of previous work, in this study, a breathing retraining component is added using breathing calisthenics and inspiratory muscle trainer for the classical cardiac rehabilitation (CR), as an appealing option, to implement a comprehensive rehabilitation protocol addressing the different patient-centered outcomes including different cardiovascular, and respiratory complaints; increasing the benefits of classical CR; detecting the impact of adding this on the cardiovascular (CV) outcomes, and discovering the correlation between the CV and respiratory data.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2019
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2020
CompletedFirst Submitted
Initial submission to the registry
May 19, 2021
CompletedFirst Posted
Study publicly available on registry
May 27, 2021
CompletedJanuary 25, 2022
January 1, 2022
9 months
May 19, 2021
January 10, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
heart rate variability
represent autonomic response of the heart (measured through a holter ECG)
12 weeks
functional capacity
represents aerobic fitness (VO2 max) (ml/kg/min) measured through cardiopulmonary exercise testing
12 weeks
anaerobic threshold
represents lactate threshold (% of VO2 max) measured through cardiopulmonary exercise testing
12 weeks
resting heart rate
represents resting condition of the heart (beat/min)
12 weeks
resting systolic blood pressure
represents resting condition of the systolic blood pressure (mmhg) measured by sphygmomanometer
12 weeks
resting diastolic blood pressure
represents resting condition of the diastolic blood pressure (mmhg) measured by sphygmomanometer
12 weeks
Secondary Outcomes (2)
forced vital capacity
12 weeks
rate of perceived exertion
12 weeks
Study Arms (2)
Cardiac rehabilitation with breathing retraining
EXPERIMENTALA cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
cardiac rehabilitation
ACTIVE COMPARATORA cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
Interventions
A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)
A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
Eligibility Criteria
You may qualify if:
- chronic heart failure (≥ 1 year) .Respiratory muscle weakness≤ 70% of their predicted MIP.
- Ages ranged from 45-65 years old
- Left ventricle ejection fraction ≤ 40% in NYHA class II and III .In stable condition (No rales on auscultation or tibial edema and with sinus rhythm).
- On standard cardiac medications (diuretics, angiotensin-converting enzyme (ACE) inhibitors, and glycosides)
- Not engaged in any regular physical training program for at least one month before the start of the study.
You may not qualify if:
- Chronic lung disorders,
- Anemia
- Severe hypoxia
- History of myocardial infarction or pulmonary edema six months before the study
- Severe uncontrolled hypertension, or uncontrolled diabetes mellitus or autonomic disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
- National Heart Institute, Egyptcollaborator
Study Sites (1)
National heart institute
Cairo, AI Qahirah, 11847, Egypt
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hady Atef, PhD
Cairo University, Egypt
- STUDY DIRECTOR
Donna Fitzimons, Prof
Queen's University, Belfast
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- CARE PROVIDER
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer of physical therapy for cardiopulmonary disorders, Faculty of Physical therapy
Study Record Dates
First Submitted
May 19, 2021
First Posted
May 27, 2021
Study Start
June 1, 2019
Primary Completion
March 1, 2020
Study Completion
March 1, 2020
Last Updated
January 25, 2022
Record last verified: 2022-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- after 1 month for12 months
- Access Criteria
- will upload it to the journal of publication
After approval can be shared